Zasocitinib's Strong Niche Psoriasis Data Can't Obscure Gaps in Competitive and Primary Endpoint Evidence

Takeda's Zasocitinib Shows Strong Efficacy in Hard-to-Treat Psoriasis Areas

Takeda has unveiled positive secondary endpoint data from two Phase III trials (NCT06088043, NCT06108544) evaluating its oral TYK2 inhibitor, zasocitinib, for moderate-to-severe plaque psoriasis (PsO). The data, presented at the 2026 AAD Innovation Academy, demonstrated consistent and high rates of skin clearance in hard-to-treat areas such as the scalp, nails, palms, and soles, compared to placebo. For scalp psoriasis, 77% and 74% of patients achieved scalp-specific PGA (ssPGA) 0/1 response with zasocitinib, significantly higher than placebo (7% and 13%) and Amgen’s Otezla (42% and 30%). Similar high rates were observed for palmoplantar psoriasis, with approximately 70% achieving hands- and/or feet-specific PGA (hfPGA) 0/1 response. Zasocitinib also showed statistically significant improvements in Nail Psoriasis Severity Index (NAPSI). These findings reinforce the drug's potential as a leading oral treatment and support Takeda's upcoming New Drug Application submission to the FDA.

• Strong Efficacy in Hard-to-Treat Psoriasis Areas: Zasocitinib demonstrated consistent and high rates of skin clearance across challenging areas like the scalp, nails, palms, and soles. In scalp psoriasis, 77% and 74% of patients achieved scalp-specific PGA (ssPGA) 0/1 response, significantly outperforming placebo (7% and 13%). For palmoplantar psoriasis, approximately 70% of patients achieved hands- and/or feet-specific PGA (hfPGA) 0/1 response, compared to 10-22% for placebo. The drug also delivered statistically significant improvements in Nail Psoriasis Severity Index (NAPSI).
• Superiority Over Existing Oral Treatments: In a separate head-to-head Phase III LATITUDE Atlas study, zasocitinib demonstrated statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib), another TYK2 inhibitor. Zasocitinib achieved a greater than 2.5 times higher Psoriasis Area and Severity Index (PASI) 100 response rate at week 16, with over 35% of patients reaching this primary endpoint. It also showed superiority across all key secondary endpoints, including PASI 90 response and Static Physician’s Global Assessment (sPGA) 0 at week 16.
• Advancing Regulatory Path and Broad Therapeutic Potential: Takeda is preparing to submit a New Drug Application (NDA) for zasocitinib in plaque psoriasis to the US FDA and other regulatory authorities, beginning this fiscal year. Beyond psoriasis, zasocitinib is also being investigated in Phase III studies for psoriatic arthritis and Phase II studies for Crohn's disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa (HS), indicating its potential across multiple immune-mediated inflammatory conditions.

Zasocitinib's Position in the Evolving PsO Treatment Landscape

Zasocitinib, an oral TYK2 inhibitor, has emerged as a notable investigational entrant in the plaque psoriasis space, with Phase 2b data (287 randomized patients, 259 treated) demonstrating clear dose-dependent efficacy. At week 12, PASI 75 response rates reached 68% and 67% at the 15 mg and 30 mg doses respectively, compared with only 6% for placebo, while PASI 90 responses tracked consistently with PASI 75 outcomes. Notably, PASI 100 clearance also showed a dose-response relationship, with 33% of patients on the 30 mg dose achieving complete skin clearance—an outcome that positions zasocitinib competitively against injectable biologics while retaining the convenience of oral administration. Treatment-emergent adverse events were modestly higher than placebo (53–62% vs. 44%) but showed no dose dependency, suggesting a manageable tolerability profile at this stage of development.

When contextualized against other oral and biologic therapies, zasocitinib's efficacy appears comparable to, or exceeding, several established options. Tofacitinib, a JAK inhibitor, achieved PASI 75 in 57.1% of patients by week 12 in a head-to-head trial against methotrexate, with a significantly higher PASI 90 rate at week 16 (57.1% vs. 19.0%, p<0.05), underscoring a broader trend of targeted oral agents delivering faster and deeper clearance than conventional systemics. Biologic therapies continue to set a high efficacy bar: real-world ixekizumab data show sustained PASI 100 rates of 30.7% at week 156, while secukinumab achieves PASI 100 in 63% of patients by week 16. Against this backdrop, zasocitinib's Phase 2b performance suggests it could occupy a differentiated niche—offering biologic-level efficacy through a convenient oral formulation—though longer-term durability and comparative safety data from Phase 3 trials will be essential to firmly establish its place relative to both conventional systemics and the growing roster of biologic and JAK/TYK2-targeted therapies.

Overall, the evolving treatment landscape reflects a broader shift away from conventional systemics such as methotrexate, cyclosporine, and phototherapy—agents constrained by cumulative toxicity, delayed onset, and monitoring burdens—toward targeted oral and biologic therapies offering faster, deeper, and more sustained skin clearance. Zasocitinib's emergence within this trajectory signals continued innovation in oral targeted therapy, potentially expanding options for patients seeking biologic-level efficacy without the burden of injectable administration, pending confirmation through late-stage clinical development.

Addressing Unmet Needs in Moderate-to-Severe Plaque Psoriasis

Despite significant advances in biologic and targeted oral therapies for moderate-to-severe plaque psoriasis, recent literature highlights persistent gaps in treatment personalization, access, and long-term disease management. Key unmet needs span specific patient populations with distinct clinical and psychosocial profiles, as well as systemic challenges around treatment burden, cost, and comorbidity management.

• Elderly patients (≥65 years): This growing population remains underrepresented in clinical trials. Real-world data (Czech Republic cohort, n=265 vs. 530 younger controls) show comparable efficacy (PASI ≤2 in ~70% across age groups at 52 weeks) but lower first-year drug survival (88% vs. 96%), particularly with adalimumab (81% vs. 99%), with treatment switching driven predominantly by loss of efficacy (86.7%) rather than adverse events.

• Patients with high comorbidity burden: Dyslipidemia (55%), hypertension (42%), and obesity (36%) are highly prevalent, with 58% of patients undergoing liver elastography meeting MASLD criteria. Comorbidity profiles differ by phenotype (e.g., plaque psoriasis with hypertension/vitamin D deficiency; erythrodermic psoriasis with alcoholism/neoplasia), underscoring the need for multidisciplinary care and primary care-led screening. Obesity is also associated with reduced biologic response (p=0.02385).

• Patients requiring long-term maintenance therapy: Indefinite biologic use in patients achieving clear/near-clear skin drives substantial treatment burden. An "as needed" biologic approach is supported by 67% of patients and 78% of clinicians, though financial dissatisfaction (38.0%) and injection-related distress (18.2%) remain prominent concerns, pointing to a need for alternative maintenance strategies such as oral therapies.

• Patients with inadequate response to biologics alone: In patients with ≥3% BSA involvement failing to respond adequately after ≥24 weeks of biologic therapy, adjunctive nonsteroidal tapinarof cream 1% enabled 52.4% to reach treat-to-target goals (≤1% BSA) by week 12, suggesting a role for combination strategies in partial responders.

• Patients with psychological and quality-of-life impact: Nearly 29% present with moderate-to-severe depressive symptoms at baseline, improving substantially with treatment (to 5.3% at follow-up). Baseline psychological symptoms are the strongest predictors of psychological and QoL outcomes, alongside PASI, female sex, psychiatric comorbidity, and prior biologic exposure—highlighting a need for integrated dermatologic-mental health care models.

• Patients needing personalized treatment approaches: Genetic (e.g., CARD14 rs34367357 mutation linked to earlier onset and higher baseline DLQI) and seasonal factors (greater PASI improvement with therapy initiated April–September) suggest opportunities for biomarker- and timing-informed treatment selection.

• Access and cost-related disparities: Biologic utilization remains limited in real-world settings (e.g., only 4.9% of psoriasis patients in Colombia received biologics in 2019), with substantial annual per-patient costs (ustekinumab: $12,880 USD; adalimumab: $7,130 USD; secukinumab: $6,825 USD), reinforcing the need for biosimilars as first-line options to improve equitable access.

• Emerging mechanisms addressing residual needs: Dual IL-17A/F inhibition (bimekizumab) and selective TYK2 inhibition (deucravacitinib) show strong efficacy and favorable safety profiles, including in biologic-experienced patients, though sustainability of complete responses (PASI 100) is lower in this subgroup—indicating continued need for optimized sequencing strategies in treatment-refractory populations.

Zasocitinib's Targeted Efficacy: A New Standard for Oral Psoriasis

The recent unveiling of positive secondary endpoint data for Takeda's oral TYK2 inhibitor, zasocitinib, represents a pivotal moment for patients grappling with moderate-to-severe plaque psoriasis, particularly those with challenging manifestations in areas like the scalp, nails, palms, and soles. These regions often prove recalcitrant to treatment, leaving a significant unmet need for effective and convenient therapies. Zasocitinib's robust performance, demonstrating high rates of skin clearance and significant improvements in Nail Psoriasis Severity Index, positions it as a strong contender to redefine the standard of care for these specific patient populations.

The strategic advantage of zasocitinib lies in its highly selective allosteric inhibition of TYK2, a mechanism that targets the crucial IL-23/IL-17 axis in psoriasis pathogenesis while aiming to mitigate the broader safety concerns associated with less selective pan-JAK inhibitors. This selectivity is a key differentiator, as the literature suggests TYK2 inhibitors generally offer a more favorable safety profile. While deucravacitinib, another oral TYK2 inhibitor, has already established its efficacy and safety, some studies indicated less consistent improvement in fingernail psoriasis, potentially creating an opening for zasocitinib to excel in this specific area.

However, the path forward is not without its challenges. The TYK2 inhibitor class is becoming increasingly competitive, with several agents in development. Takeda will need to navigate this crowded landscape, emphasizing zasocitinib's unique strengths, especially its targeted efficacy in hard-to-treat areas. Furthermore, while initial safety data for TYK2 inhibitors are encouraging, long-term safety and durability of effect will be critical for widespread adoption, requiring continued monitoring and potentially longer-duration studies to build a comprehensive profile comparable to the multi-year data available for deucravacitinib. The convenience of an oral therapy, combined with potent efficacy in previously difficult-to-treat areas, holds immense promise for improving patient quality of life and adherence, potentially making zasocitinib a cornerstone in the evolving oral psoriasis therapeutic armamentarium.